BioSpace News Archive

MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics , Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.

Spero Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an update on its business and pipeline.

Inhibikase Therapeutics, Inc. today announced that Dr. Milton Werner, Ph.D., President & Chief Executive Officer of Inhibikase, will deliver a presentation at the Sidoti Micro-Cap Virtual Conference being held on May 10-11, 2023.

Sonoma Biotherapeutics, Inc. announced that its Co-founder and Chief Executive Officer, Jeffrey Bluestone, Ph.D., has been elected to the National Academy of Sciences, in recognition of his groundbreaking achievements in immunology and original research.

Agilent Technologies Inc. announced that Dr. Jiangbin Ye has received an Agilent Solutions Innovation Research Award.

Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial.

Veru Inc. (NASDAQ: VERU) today announced that in an April 27, 2023 meeting, the Company and FDA reached agreement on the design of the Phase 3 confirmatory COVID-19 clinical trial to evaluate sabizabulin treatment in hospitalized moderate to severe COVID-19 patients who are at high risk for acute respiratory distress syndrome (ARDS) and the path forward to submit a new Emergency Use Authorization (EUA) application and/or New Drug Application (NDA).

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced positive topline data for the cohort of patients with acute myeloid leukemia (AML) from its Phase 1 dose-escalation trial in relapsed/refractory (r/r) myeloid malignancies for GFH009, its CDK9 inhibitor.

ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it received a US patent certificate, US 11,554,154 B2, for PDC-1421, for the treatment of Major Depressive Disorder (MDD) on April 25, 2023.

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three months ended March 31, 2023.